Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Zai Lab soars on positive data from partner's cancer therapy

** U.S.-listed shares of Chinese biopharma co Zai Lab Ltd
 ZLAB.O  surge 33% to $45 premarket on positive data from a
late-stage study of cancer therapy by partner Novocure  NVCR.O  
    ** Novocure shares up 74% at $123 premarket
    ** Brokerage Jefferies says data is a "positive surprise"
and should help invigorate co's pipeline value
    ** Brokerage expects ZLAB to submit the data to the Chinese
drug regulator to obtain approval in the country as a
second-line treatment for non-small cell lung cancer
    ** Novocure had granted ZLAB a license to commercialize the
therapy called Tumor Treating Fields (TTF) in Greater China in
2018
    ** TTF uses electric fields tuned to specific frequencies to
disrupt cell division, inhibiting tumor growth and causing
affected cancer cells to die
    ** ZLAB shares had declined 51% in 2022
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))

Recent news on Zai Lab

See all news